Chilling scalp to save hair to be put to the test in U.S.
By The Associated Press
Published: Monday, July 22, 2013, 7:21 p.m.
WASHINGTON — Hair loss is one of chemotherapy's most despised side effects, not because of vanity, but because it fuels stigma — revealing to the world an illness that many would rather keep private.
Now, American researchers are about to put an experimental hair-preserving treatment to a rigorous test: To see whether strapping on a cap so cold it numbs the scalp during chemotherapy works well enough to be used widely in this country, as it is in Europe and Canada.
The first time Miriam Lipton had breast cancer, her thick locks fell out within two weeks of starting chemotherapy. When the disease struck again, she used a cold cap during treatment and kept much of her hair, making her fight for survival seem a bit easier.
“I didn't necessarily want to walk around the grocery store answering questions about my cancer,” recalled Lipton, 45, of San Francisco. “If you look OK on the outside, it can help you feel, ‘OK, this is manageable, I can get through this.' ”
Near-freezing temperatures are supposed to reduce blood flow in the scalp, making it harder for cancer-fighting drugs to reach and harm hair follicles. But while several types of cold caps are sold around the world, the Food and Drug Administration hasn't approved their use in the United States.
Scalp cooling is an idea that has been around for decades, but it never caught on here in part because of a concern: Could the cold prevent chemotherapy from reaching any stray cancer cells lurking in the scalp?
“Do they work, and are they safe? Those are the two big holes. We just don't know,” said American Cancer Society spokeswoman Kimberly Stump-Sutliff, an oncology nurse who said studies abroad haven't settled those questions. “We need to know.”
To Dr. Hope Rugo of the University of California, San Francisco, the impact of hair loss has been overlooked, even belittled, by health providers. She has had patients delay crucial treatment to avoid it, and others whose businesses suffered when clients saw they were sick and shied away.
With more people surviving cancer, “we need to make this experience as tolerable as possible, so there's the least baggage at the end,” Rugo said.
“Quite frankly, it's the first or second question out of most patients' mouths when I tell them I recommend chemotherapy. It's not, ‘Is this going to cure me? It's, ‘Am I going to lose my hair?' ” adds Dr. Susan Melin of North Carolina's Wake Forest Baptist Medical Center.
Later this summer, Rugo and Melin, along with researchers at a few other hospitals in New York and California, will begin enrolling 110 early-stage breast-cancer patients in a study of the DigniCap brand of scalp cooling. The tight-fitting, insulated cap is attached to a cooling machine to stay around a shivery 41 degrees as patients undergo chemo. Participants' hair will be photographed for experts to assess, and they'll be compared with a small group of similarly ill patients who get chemo alone.
Lipton was among 20 U.S. patients who pilot-tested the DigniCap in 2011, most of whom kept more than half of their hair. Lipton's thinned quite a bit at the crown, where the cap didn't fit snugly. But because her bangs and surrounding hair remained, the mother of two covered the thinning area with a headband, not a wig. The side effect: pain and a headache as the cold set in.
“It wasn't perfect, but it was easier,” said Lipton, who is healthy today.
If the larger study is successful, Sweden's Dignitana AB plans to seek FDA approval to market the medical device in the United States. The move could open the way for other brands and insurance coverage.
Clearly, there's demand: Despite the lack of FDA approval, a growing number of U.S. patients are renting a similar product, called Penguin Cold Caps, from a British company for $455 a month. Patients haul a collection of caps to chemo sessions on dry ice or store them in special freezers provided by about 50 hospitals. It's deliberately separate from doctors' and nurses' care — typically, patients bring a friend to help them switch caps every 20 to 30 minutes when one loses its chill.
Beyond breast cancer, advocates say the caps may be useful with other solid tumors.
What's the evidence behind scalp cooling? A recent review by oncologists in the Netherlands found numerous overseas studies conclude scalp cooling can work — but it's far from clear which patients are most likely to benefit, even how cold the scalp should be. That's because most of the research has been from observational studies that can't provide proof. But it seems harder to save hair with higher doses and certain types of chemo.
Researchers at New York's Weill Cornell Breast Center reported at a recent meeting of the American Society for Clinical Oncology that among just over a dozen Penguin cap users, one lost enough hair to use a wig.
As for safety, UCSF's Rugo said a recurring tumor in the scalp is incredibly rare.
Hair-preserving approaches need good testing, adds Dr. Laura Esserman, a UCSF breast-cancer specialist.
“If it matters to our patients, it should matter to us,” she said. “It's really not more complicated than that.”
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- Authorities say they have trove of evidence against Dzhokhar Tsarnaev in Boston Marathon bombing
- Subsitute for Pap smear scorned; overtreatment cited
- Court upholds EPA emissions restrictions
- T. rex gets the red-carpet treatment at Smithsonian
- Bankrupt Detroit, retired cops, fire crews agree to deal that saves pensions
- Additional sanctions possible against Russia
- GPS leads police to 2 ex-cons in Calif. killings
- Investment analyst to get Medal of Honor
- Study says regular pot use affects the brain
- Somber Boston marks first anniversary of marathon bombing
- Rural Texas town where fertilizer plant exploded to consider fostering new facility